Sildenafil or vardenafil nonresponders' erectile response to tadalafil

Urology Journal

Volumn 6, Issue 4, 2009, Pages 267-271

  Ozgur, Berat Cem ^a,c   Gonenc, Faruk ^b   Yazicioglu, Ahmet H ^b  

^a Gazi Hospital   (Turkey)

^b Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

^c Libya St 62 17 06650 ^*  (Turkey)

Author keywords

Erectile dysfunction; Sildenafil; Tadalafil; Treatment failure; Vardenafil

Indexed keywords

CARBOLINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE; TADALAFIL; TRIAZINE DERIVATIVE; VARDENAFIL;

AGED; ARTICLE; CLINICAL TRIAL; ERECTILE DYSFUNCTION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; TREATMENT FAILURE;

AGED; CARBOLINES; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TREATMENT FAILURE; TRIAZINES;

EID: 77951227017     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lue TF. Erectile dysfunction. N Engl J Med. 2000; 342:1802-13.
2. McMahon CG. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res. 2002; 14:533-538
3. Becker AJ, Uckert S, Stief CG. The basics of phosphodiesterase type 5 (PDE5) inhibition in urology. Urologe A. 2008; 47:1582-1587
4. Deng SM. Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours. Zhonghua Nan Ke Xue.2008; 14:857-860
5. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002; 11:1605-1613
6. Rosen R, Riley A, Wagner G, et al. The international index of erectile function (HEF): A multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822-830
7. Curran M, Keating G. Tadalafil. Drugs. 2003; 63:2203-2212
8. Savas M, Yenl E, Ciftci H, Topal U, Utangac M, Verit A. Is Penile Length a Factor in Treatment of Erectile Dysfunction with PDE-5 Inhibitor? J Androl. 2009; 30:515-519
9. Rendell MS, Raifer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999; 3; 281:421-426
10. Aubin S, Heiman JR, Berger RE, Murallo AV, YungWen L. Comparing Sildenafil alone vs. Sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. J Sex Marital Ther. 2009; 35:122-143
11. Montorsi F, Padma Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional wellbeing, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate. Urology. 2006; 68:26-37.
12. Hellstrom WJG, Elhilali M, Homering M, et al. Vardenafil In patients with erectile dysfunction: Achieving treatment optimization. J Androl. 2005; 26:604-609
13. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs. 2004; 64:2667-2688
14. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. 2006; 60:967-975
15. Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, Wang WC, Kopemicky V. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl. 2006; 8:685-692
16. Syed T. Effectiveness of sildenafil citrate and tadalafil on sexual responses in Saudi men with erectile dysfunction in routine clinical practice. Pak J Pharm Sci. 2008; 21:275-281
17. Chelsea N, McMahon, Christopher J Smith, Ridwan Shabsigh. Treating erectile dysfunction when PDE-5 inhibitors fail. BMJ. 2006; 332:589-592